ABT vs AMD Stock Comparison

Scores Breakdown

Metric	ABT	AMD
📈 Growth	22/30	28/30
💰 Profitability	17/20	16/20
🏦 Financial Health	15/20	18/20
💵 Valuation	12/20	15/20
⚠️ Risk (lower is better)	4/10	7/10
Overall Score	72/100	80/100

Side-by-Side Summaries

ABT Analysis	AMD Analysis
📈 Growth & Financial Trajectory Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects). 💰 Margins & Cash Flow Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest. 🛡️ Balance Sheet & Liquidity Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience. ⚠️ Key Drivers & Risks Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios. Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.	📈 Growth & Financial Trajectory Over the eight quarters, Revenues rose from roughly $7.44B to about $10.25B, a sustained upshift with a brief mid-period pause. Net Income climbed from about $0.264B to $1.383B, with quarterly oscillations but a clear uptrend (peaks in 2025 Q4 and 2026 Q1). 💰 Margins & Cash Flow Gross margins held near 50-54%, with quarterly gross profit around $3.0-5.6B on rising revenues. Operating margins stayed in the mid-teens (~14-17%), reflecting improving operating leverage as volumes grow. Cash flow from operations was positive in each period (approx. $1.0-3.0B per quarter), with investing cash outflows offset by financing activity and net cash flow turning positive in several quarters. 🛡️ Balance Sheet & Liquidity Equity attributable to parent ranges around $58-64B with total assets near $69-79B. Current assets about $19-28B and current liabilities around $7-10B yield a healthy liquidity cushion. Debt levels remain modest relative to equity, supporting resilience. ⚠️ Key Drivers & Risks Drivers: AI/Data Center GPU demand; AMD product cadence and process technology advantages. Risks: Semiconductor cyclicality and valuation sensitivity to growth trajectories; competitive pressure in a consolidating GPU/CPU market.

ABT Analysis

AMD Analysis

📈 Growth & Financial Trajectory

Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects).

💰 Margins & Cash Flow

Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest.

🛡️ Balance Sheet & Liquidity

Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience.

⚠️ Key Drivers & Risks

Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios.
Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues rose from roughly $7.44B to about $10.25B, a sustained upshift with a brief mid-period pause. Net Income climbed from about $0.264B to $1.383B, with quarterly oscillations but a clear uptrend (peaks in 2025 Q4 and 2026 Q1).

💰 Margins & Cash Flow

Gross margins held near 50-54%, with quarterly gross profit around $3.0-5.6B on rising revenues. Operating margins stayed in the mid-teens (~14-17%), reflecting improving operating leverage as volumes grow. Cash flow from operations was positive in each period (approx. $1.0-3.0B per quarter), with investing cash outflows offset by financing activity and net cash flow turning positive in several quarters.

🛡️ Balance Sheet & Liquidity

Equity attributable to parent ranges around $58-64B with total assets near $69-79B. Current assets about $19-28B and current liabilities around $7-10B yield a healthy liquidity cushion. Debt levels remain modest relative to equity, supporting resilience.

⚠️ Key Drivers & Risks

Drivers: AI/Data Center GPU demand; AMD product cadence and process technology advantages.
Risks: Semiconductor cyclicality and valuation sensitivity to growth trajectories; competitive pressure in a consolidating GPU/CPU market.

Similar Companies

ABBV Score: 59 BSX Score: 81 ELV Score: 77 ISRG Score: 85 JNJ Score: 79 MDT Score: 67 TMO Score: 75 TSLA Score: 62

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"